Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
October 30, 2018 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
Dr. Anish Suri, Cue Biopharma’s CSO, to Present at Upcoming Precision: Lung Cancer Summit
October 24, 2018 08:00 ET
|
Cue Biopharma, Inc.
Overview and Update on the ImmunoSTAT™ Platform for Selective Targeting of Disease-Relevant T cells CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an...
Cue Biopharma Announces Strategic Research Collaboration with Albert Einstein College of Medicine to Further the Potential of Immuno-STAT™ Platform in Chronic Infectious Diseases
October 17, 2018 08:00 ET
|
Cue Biopharma, Inc.
Collaboration Expands Platform’s Reach Beyond Cancer and Autoimmune Disease to Address T cell Exhaustion in Chronic Infectious Diseases CAMBRIDGE, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Cue...
Cue Biopharma Appoints Hon. Randall R. Rader to Chair Company’s Intellectual Property Committee
October 03, 2018 09:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
Cue Biopharma to Host Investor Business Update Call and Webcast
August 14, 2018 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors
August 03, 2018 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to...
Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice President
July 24, 2018 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to...
Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
July 12, 2018 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human...
Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee
June 28, 2018 09:15 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to...
Cue Biopharma to Host Investor Business Update Call and Webcast
May 10, 2018 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively...